Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP-O feasibility study in newly diagnosed Richter's syndrome
ISRCTN88860946Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Apr 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab, cyclophosphamide, doxorubicin, vincristine, prednisone and 1 more in Richter's syndrome (RS), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Oxford. Primary endpoint: Objective response. Started Apr 2011; status: completed.
02
Drugs
ofatumumabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
Richter's syndrome (RS)diffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN88860946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN88860946.